Addex Therapeutics (ADXN) News
NASDAQ: ADXNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
3.22+0.0386 (+1.21%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
ADXN news summary
We found 2 recent headlines mentioning Addex Therapeutics (ADXN): 2 in the past week and 2 in the past 30 days, most often from Nasdaq, GlobeNewswire. For price context, ADXN is up 1.21% at $3.22. The most recent story, "Addex Spin-Out Neurosterix Takes NTX-253 Closer To Phase 2 Schizophrenia Trial", was published by Nasdaq on Oct 8, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Addex Therapeutics headlines
- Addex Spin-Out Neurosterix Takes NTX-253 Closer To Phase 2 Schizophrenia Trial(RTTNews) - Addex Therapeutics (ADXN) announced that its spin-out company Neurosterix has completed Phase 1 clinical studies of NTX-253, an investigational positive allosteric modulator (PAM) of the…NasdaqADXN, ET
- Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for SchizophreniaAd Hoc Announcement Pursuant to Art. 53 LRGlobeNewswire